Medical researchers unite for study on cancer intervention

We introduce Drs. Antoine Snijders and Jian-Hua Mao, whose article is published in this issue of AMOR and discuss their views on cancer genetics, targeted therapy, and personalized medicine.Having worked together in numerous joint investigations that have yielded significant results, Dr. Snijders and Dr. Mao would most definitely agree that two heads are better than one. “Researchers these days need to have the ability to collaborate across many different disciplines,” said the duo in an exclusive interview with AMOR. Dr. Snijders and Dr. Mao, both with PhDs in cancer genetics and genomics, are currently based at the Biological Systems and Engineering Division of Lawrence Berkeley National Laboratory, California, which is a member of the national laboratory system supported by the U.S Department of Energy through its Office of Science.    The Berkeley Lab is well known for producing excellent scholars, as thirteen Nobel Prize winners are affiliated with the Lab and seventy of its scientists are members of the National Academy of Sciences (NAS), one of the highest honors for a scientist in the United States. Dr. Snijders, a Dutch who has conducted his research at Berkeley Lab for the past eight years, did his Masters in Science (Medical Biology) at the Vrije Universiteit Amsterdam, Netherlands – an institute with a strong focus on scientific research and is home to five Spinoza Prize (a.k.a. the “Dutch Nobel”) winners.   Dr. Snijders’s PhD ( cum laude ) in cancer and molecular biology was awarded by University Utrecht in Netherlands, but his research work was carried out at the University of California San Francisco. Subsequently, he continued his postdoctoral research in molecular cytogenetics at the same institution. A prolific author of 114 publications (with 3,851 citations) according to ResearchGate, Dr. Snijders – who also volunteers with California’s Contra Costa County Search and Rescue team for missing persons – has interests in the areas of molecular biology, cell biology, and cancer research.   Some of the awards received by Dr. Snijders include the prestigious President’s Award for Excellence and the Student Travel Award at the 2014’s XXII International Congress of the International Society for Analytical Cytology in Montpellier, France. He was also the co-recipient of the AACR Team Science Award for the conception, technical implementation, dissemination, and pioneering applications of an array comparative genomic hybridization technique from the American Association of Cancer Research in 2008.   Meanwhile, Dr. Mao studied applied mathematics at Southeast University, Nanjing, China, and pursued his masters in biostatistics and cancer epidemiology at Beijing Medical University (now Peking University Health Science Center). In 1988, Dr. Mao received the Outstanding Postgraduate Award from Beijing Medical University and two years later, was awarded an Outstanding Lecturer Award from the same university. He then pursued his PhD in cancer genetics at the Department of Radiation Oncology, University of Glasgow, UK. During this period, Dr. Mao was awarded the Oversea Research Student Awards from the Committee of Vice-Chancellor and Principals of the Universities of the United Kingdom, along with the Glasgow University Travel fellowship.   Dr. Snijders and Dr. Mao joined Berkeley Lab in 2008 as resident scientist and genetic staff scientist, respectively, where their work focuses on using the multi-omics approach to identify critical genes as potential therapeutic targets and prognostic biomarkers. “At the same time, we investigate underlying biological mechanisms and functions using different model systems, including genetically engineered mouse models,” they told AMOR.   “Mouse models offer many advantages for the study of the genetic basis of complex traits, including radiation-induced cancers, because of our ability to control both the genetic and environmental components of risk. The goal is the understanding of all stages of multi-step carcinogenesis in the mouse, in particular the relationships between germ line predisposition and somatic genetic changes in tumors.” explained Dr. Mao in a news feature released by Berkeley Lab. “The identification of human homologues of these predisposition genes and the   discovery of their roles in carcinogenesis will ultimately be important for the development of methods for the prediction of risk, diagnosis, prevention, and therapy for human cancers,” he further added.    “Although targeted therapy has given hope to patients, drug resistance usually takes place within short time. We need to figure out a way to combine multiple  targeted therapies to treat patient s and somehow circumvent drug resistance to cure cancer.”Both scientists confessed to having a deep interest in the biology of cancer, which motivates them to focus their efforts in developing therapeutics as cancer intervention. However, they are sometimes subdued by numerous challenges in their research works, namely the heterogeneity and complexity of the tumors, which make it difficult to successfully treat patients. In addition, they highlighted a common challenge in their field, which also happens to be one of the main concerns for a majority of cancer researchers all over the world – lack of funding for research. “It remains challenging to obtain sufficient funds to do the research we believe is important,” they said.   When asked for their opinion of targeted therapy, which is a growing part of many cancer treatment regimens, both scientists claimed, “Although targeted therapy has given hope to patients, drug resistance usually takes place within a short time. We need to figure out a way to combine multiple targeted therapies to treat patients and somehow circumvent drug resistance to cure cancer.” For researchers who are studying the biology of cancer, Dr. Snijders and Dr. Mao believe that they should ideally take into account individual genetic variation and environmental factors to study human’s susceptibility to complex diseases. This would in turn allow the researchers to execute personalized medicine in a clinical setting. “In the future, we envision an increase in disease treatment and prevention that take into account the individual genetic variation,” they concluded. Drs. Antoine Snijders and Jian-Hua Mao publish their work entitled “Multi-omics approach to infer cancer therapeutic targets on chromosome 20q across tumor types” in this issue of AMOR (page 215–223).